Inserm, U 791, LIOAD, Nantes, F-44042, France.
Curr Stem Cell Res Ther. 2009 Dec;4(4):318-29. doi: 10.2174/157488809789649205.
Injuries to articular cartilage are one of the most challenging issues of musculoskeletal medicine due to the poor intrinsic ability of this tissue for repair. Despite progress in orthopaedic surgery, the lack of efficient modalities of treatment for large chondral defects has prompted research on tissue engineering combining chondrogenic cells, scaffold materials and environmental factors. The aim of this review is to focus on the recent advances made in exploiting the potentials of cell therapy for cartilage engineering. These include: 1) defining the best cell candidates between chondrocytes or multipotent progenitor cells, such as multipotent mesenchymal stromal cells (MSC), in terms of readily available sources for isolation, expansion and repair potential; 2) engineering biocompatible and biodegradable natural or artificial matrix scaffolds as cell carriers, chondrogenic factors releasing factories and supports for defect filling, 3) identifying more specific growth factors and the appropriate scheme of application that will promote both chondrogenic differentiation and then maintain the differentiated phenotype overtime and 4) evaluating the optimal combinations that will answer to the functional demand placed upon cartilage tissue replacement in animal models and in clinics. Finally, some of the major obstacles generally encountered in cartilage engineering are discussed as well as future trends to overcome these limiting issues for clinical applications.
关节软骨损伤是肌肉骨骼医学中最具挑战性的问题之一,因为这种组织的内在修复能力很差。尽管矫形外科取得了进展,但对于大面积软骨缺损缺乏有效的治疗方法,促使人们研究将软骨细胞、支架材料和环境因素结合起来的组织工程。本文旨在重点介绍细胞疗法在软骨工程中的最新进展。这些进展包括:1)根据分离、扩增和修复潜力的易得性,确定软骨细胞或多能祖细胞(如多能间充质基质细胞[MSC])中最佳的候选细胞;2)设计生物相容性和可生物降解的天然或人工基质支架作为细胞载体、软骨形成因子释放工厂和缺陷填充的支撑物;3)确定更具体的生长因子和应用方案,以促进软骨形成分化,并随着时间的推移维持分化表型;4)评估最佳组合,以满足动物模型和临床中对软骨组织替代的功能需求。最后,还讨论了软骨工程中通常遇到的一些主要障碍,以及未来克服这些限制因素以实现临床应用的趋势。